Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MNPR NASDAQ:PRQR NASDAQ:SLRN OTCMKTS:VICP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMNPRMonopar Therapeutics$44.67+21.2%$35.55$1.72▼$54.30$272.76M1.01361,865 shs110,136 shsPRQRProQR Therapeutics$2.44+5.2%$1.86$1.07▼$4.62$257.24M0.36660,156 shs200,554 shsSLRNAcelyrin$2.27$2.28$1.85▼$7.25$229.17M1.071.29 million shsN/AVICPSSGI$1.77$1.77$1.25▼$3.00$57.30M-4.58N/AN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMNPRMonopar Therapeutics0.00%+2.79%+9.99%-1.65%+936.11%PRQRProQR Therapeutics0.00%+8.26%+23.40%+96.61%+25.41%SLRNAcelyrin0.00%0.00%0.00%+4.13%-60.18%VICPSSGI0.00%0.00%0.00%0.00%-64.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMNPRMonopar Therapeutics2.1815 of 5 stars3.42.00.00.03.21.70.0PRQRProQR Therapeutics2.5406 of 5 stars3.65.00.00.02.60.00.0SLRNAcelyrinN/AN/AN/AN/AN/AN/AN/AN/AVICPSSGI0.064 of 5 stars0.03.00.00.00.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMNPRMonopar Therapeutics 2.83Moderate Buy$60.0034.32% UpsidePRQRProQR Therapeutics 3.13Buy$8.00227.87% UpsideSLRNAcelyrin 2.40Hold$9.60322.91% UpsideVICPSSGI 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VICP, SLRN, MNPR, and PRQR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025PRQRProQR TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform7/7/2025MNPRMonopar TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$74.006/27/2025PRQRProQR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$8.006/27/2025PRQRProQR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.006/23/2025MNPRMonopar TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.005/13/2025PRQRProQR TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $9.004/29/2025PRQRProQR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$8.004/29/2025PRQRProQR TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.00(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/APRQRProQR Therapeutics$20.46M12.55N/AN/A$0.91 per share2.68SLRNAcelyrinN/AN/AN/AN/A$6.74 per shareN/AVICPSSGIN/AN/AN/AN/A($0.06) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMNPRMonopar Therapeutics-$15.59M-$3.48N/AN/AN/AN/A-55.39%-51.53%8/8/2025 (Estimated)PRQRProQR Therapeutics-$30.04M-$0.35N/AN/AN/A-157.04%-53.49%-22.07%8/4/2025 (Estimated)SLRNAcelyrin-$381.64M-$2.69N/AN/AN/AN/A-44.12%-39.02%8/12/2025 (Estimated)VICPSSGI-$1.18M-$0.04N/A∞N/AN/AN/AN/AN/ALatest VICP, SLRN, MNPR, and PRQR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025N/AMNPRMonopar Therapeutics-$0.47N/AN/AN/AN/AN/A5/14/2025Q1 2025SLRNAcelyrin-$0.95-$0.55+$0.40-$0.55N/AN/A5/13/2025Q1 2025MNPRMonopar Therapeutics-$0.65-$0.38+$0.27-$0.38N/AN/A5/8/2025Q1 2025PRQRProQR Therapeutics-$0.09-$0.1082-$0.0182-$0.11$4.90 million$4.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMNPRMonopar TherapeuticsN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ASLRNAcelyrinN/AN/AN/AN/AN/AVICPSSGIN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMNPRMonopar TherapeuticsN/A36.9136.91PRQRProQR TherapeuticsN/A4.104.10SLRNAcelyrinN/A7.157.15VICPSSGIN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMNPRMonopar Therapeutics1.83%PRQRProQR Therapeutics32.65%SLRNAcelyrin87.31%VICPSSGIN/AInsider OwnershipCompanyInsider OwnershipMNPRMonopar Therapeutics20.50%PRQRProQR Therapeutics8.40%SLRNAcelyrin13.60%VICPSSGI5.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMNPRMonopar Therapeutics106.12 million4.86 millionNot OptionablePRQRProQR Therapeutics180105.21 million96.38 millionOptionableSLRNAcelyrin135100.95 million86.68 millionOptionableVICPSSGI232.37 million30.44 millionNot OptionableVICP, SLRN, MNPR, and PRQR HeadlinesRecent News About These CompaniesReviewing SSGI (OTCMKTS:VICP) and Loma Negra Compania Industrial Argentina (NYSE:LOMA)July 8, 2025 | americanbankingnews.comBritish Science Week - Teaching ResourcesNovember 6, 2024 | bbc.co.ukBest term life insurance: Expert-rated in April 2024April 28, 2024 | usatoday.comScanning Electron Microscopy for the Life SciencesApril 20, 2024 | cambridge.orgCEY Life SciencesApril 8, 2024 | pmlive.comPLife ScienceJanuary 30, 2024 | dmagazine.comDCaris Life SciencesNovember 30, 2023 | dmagazine.comDAnavex Life Sciences Corp AVXLNovember 4, 2023 | morningstar.comMVICP - Vicapsys Life Sciences, Inc.August 9, 2023 | finance.yahoo.comViCapsys files for Nasdaq uplisting, $8M public offeringJuly 3, 2023 | msn.comLife sciences sector to get £650m boost in new Government funding packageJune 9, 2023 | aol.co.ukA‘Not Seeing Any Activity At All’: Once-Hot Life Sciences Leasing Market FreezesApril 1, 2023 | bisnow.comBThe Science of LifeMarch 29, 2023 | nature.comNThe ultimate list of leaders in life sciences.March 16, 2023 | statnews.comSDefining life and personhood: What science, philosophy, and religion have to sayMarch 13, 2023 | kcrw.comKLife Sciences Innovator Category Winner 2023February 23, 2023 | news-medical.netNGlobal law firm Goodwin is setting up a Philly tech, startups and life sciences practiceFebruary 20, 2023 | technical.lyTGlobal Life Science Tools Strategic Business Report 2023: Rapid Growth in Biopharma Industry and Rising Investments in R&D to Boost Market ProspectsFebruary 19, 2023 | benzinga.comFocused exclusively on life sciences, three top investors set out on their ownJanuary 28, 2023 | statnews.comSTop risks for life sciences sector revealed – reportJanuary 15, 2023 | canadianlawyermag.comCNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVICP, SLRN, MNPR, and PRQR Company DescriptionsMonopar Therapeutics NASDAQ:MNPR$44.67 +7.80 (+21.15%) As of 02:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.ProQR Therapeutics NASDAQ:PRQR$2.44 +0.12 (+5.17%) As of 02:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.Acelyrin NASDAQ:SLRN$2.27 0.00 (0.00%) As of 05/21/2025Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.SSGI OTCMKTS:VICP$1.77 0.00 (0.00%) As of 07/11/2025Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling Hits Market Leaders—Should You Be Worried? MP Materials Stock Booms on New Government Positioning MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? 3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Analysts Bet Big on Uber Stock's Expansion in Autonomous Driving Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
